Login to Your Account



Pharma: Other News To Note


Tuesday, March 12, 2013
• Moberg Derma AB, of Stockholm, Sweden, said it is discontinuing the development of Limtop, a formulation of imiquimod, in actinic keratosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription